Strong scientific proof for the Haermonics solution now available online in EClinical Medicine, published by the Lancet.
Today, the results of our second randomized clinical trial (RCT) were published online.
The price winning study (“the Pearl” by ZonMW) describes the effect of CPPF in a group of cardiac surgery patients undergoing coronary artery bypass grafting. A strong reduction in blood loss with 76% was measured in the study group when compared to the standard care group.
Moreover, when we pooled our data of this study with the outcome of the previous RCT https://www.sciencedirect.com/science/article/pii/S2352396420301195 clinically important secondary endpoints became strongly significant in favor of the CPPF study group; re-interventions for non-surgical bleeding or acute cardiac tamponade (CPPF groups 0 versus 8 in the standard care group, p = 0.007).
The freedom of these complications in the CPPF groups underline the proof of concept that CPPF is able to minimize or even eliminate these sometimes life-threatening complications after cardiac surgery.
The open access publication is available online with free PDF download: https://authors.elsevier.com/sd/article/S2589537020304053